Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Dostarlimab / jemperli for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency as of May 2025

MARA Rating Company December 16, 2025

Crysvita / burosumab for treating X-linked hypophosphataemia in adults as of August 2024

MARA Rating Company December 16, 2025

Cabotegravir / rilpivirine for treating HIV-1 infection as of January 2022

MARA Rating Company December 16, 2025

Cabometyx / cabozantinib for treating advanced hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib as of December 2022

MARA Rating Company December 16, 2025

Cabometyx / cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine as of November 2023

MARA Rating Company December 16, 2025

Cabozantinib / nivolumab for untreated advanced renal cell carcinoma as of April 2024

MARA Rating Company December 16, 2025

Epidyolex for treating seizures caused by tuberous sclerosis complex as of March 2023

MARA Rating Company December 16, 2025

Capivasertib for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment as of May 2025

MARA Rating Company December 16, 2025

Kyprolis / carfilzomib for treating multiple myeloma in adults who have had only 1 previous therapy, which included bortezomib as of April 2021

MARA Rating Company December 16, 2025

Cemiplimab for treating advanced cutaneous squamous cell carcinoma as of June 2022

MARA Rating Company December 16, 2025